ASH – American Society of Hematology – Annual Meeting – December 7, 2025
Heather Landau, Shahzad Raza, Aaron Rosenberg, Jeffrey Zonder, Raymond Comenzo, Vaishali Sanchorawala, Michaela Liedtke, Amandeep Godara, Michael Rosenzweig, Charlotte Hughes, Eugene Brailovski, Mehrdad Abedi, Sham Mailankody, Jae Park, David Marks, Sridevi Rajeeve, Jennifer Liu. Initial Safety and Efficacy Data from Nexicart-2, the First U.S. Trial of a CAR-T (NXC-201) in Relapsed or Refractory (R/R) Light Chain (AL). ASH Annual Meeting. Orlando, FL. December 7, 2025.
ASH – American Society of Hematology– Annual Meeting – December 7, 2025
ASTCT – American Society for Transplantation and Cellular Therapy – Annual Meeting – February 2026
Heather Landau, Shahzad Raza, Aaron Rosenberg, Raymond Comenzo, Amandeep Godara, Jeffrey Zonder, Vaishali Sanchorawala, Jonathan Kaufman, Al-Ola Abdallah, Michaela Liedtke, Binoy Yohannan, Larry Anderson, Michael Rosenzweig, Hamza Hashmi, Charlotte Hughes, Eugene Brailovski, Mehrdad Abedi, Sham Mailankody, Jae Park, David Marks, Sridevi Rajeeve, Jennifer Liu. First 23-Patient Safety and Efficacy Data from Nexicart-2, the First U.S. Trial of CAR-T in R/R Light Chain (AL) Amyloidosis, NXC-201. ASTCT Annual Meeting. Salt Lake City, UT, February 2026
ASTCT – American Society for Transplantation and Cellular Therapy – Annual Meeting – February 2026
Heather Landau, Shahzad Raza, Aaron Rosenberg, Raymond Comenzo, Amandeep Godara, Jeffrey Zonder, Vaishali Sanchorawala, Jonathan Kaufman, Al-Ola Abdallah, Michaela Liedtke, Binoy Yohannan, Larry Anderson, Michael Rosenzweig, Hamza Hashmi, Charlotte Hughes, Eugene Brailovski, Mehrdad Abedi, Sham Mailankody, Jae Park, David Marks, Sridevi Rajeeve, Jennifer Liu. First 23-Patient Safety and Efficacy Data from Nexicart-2, the First U.S. Trial of CAR-T in R/R Light Chain (AL) Amyloidosis, NXC-201. ASTCT Annual Meeting. Salt Lake City, UT, February 2026
ASH – American Society of Hematology – Annual Meeting – December 7, 2025
Heather Landau, Shahzad Raza, Aaron Rosenberg, Jeffrey Zonder, Raymond Comenzo, Vaishali Sanchorawala, Michaela Liedtke, Amandeep Godara, Michael Rosenzweig, Charlotte Hughes, Eugene Brailovski, Mehrdad Abedi, Sham Mailankody, Jae Park, David Marks, Sridevi Rajeeve, Jennifer Liu. Initial Safety and Efficacy Data from Nexicart-2, the First U.S. Trial of a CAR-T (NXC-201) in Relapsed or Refractory (R/R) Light Chain (AL). ASH Annual Meeting. Orlando, FL. December 7, 2025.
ASCO – American Society of Clinical Oncology – Annual Meeting – June 3, 2025
Heather J. Landau, MD, Charlotte Hughes, MD, Aaron Seth Rosenberg, MD, Mehrdad Abedi, MD, Shahzad Raza, MD, Jeffrey A. Zonder, MD, Eugene Brailovski, MD, Sergio Giralt, MD, Sham Mailankody, MBBS, Jae H. Park, MD, Miguel-Angel Perales, MD, Saad Z Usmani, MD, David Marks, MBBS, PhD, Raymond Comenzo, MD, Sridevi Rajeeve, MD, Jennifer Liu, MD. Initial Safety and Efficacy Data from Nexicart-2, the First U.S. Trial of a CAR-T (NXC-201) in Relapsed or Refractory (R/R) Light Chain (AL). ASCO Annual Meeting. Chicago, IL, June 3, 2025.
ASCO – American Society of Clinical Oncology – Annual Meeting – June 3, 2025
ASCO – American Society of Clinical Oncology – Annual Meeting – June 3, 2025
Heather J. Landau, MD, Charlotte Hughes, MD, Aaron Seth Rosenberg, MD, Mehrdad Abedi, MD, Shahzad Raza, MD, Jeffrey A. Zonder, MD, Eugene Brailovski, MD, Sergio Giralt, MD, Sham Mailankody, MBBS, Jae H. Park, MD, Miguel-Angel Perales, MD, Saad Z Usmani, MD, David Marks, MBBS, PhD, Raymond Comenzo, MD, Sridevi Rajeeve, MD, Jennifer Liu, MD. Initial Safety and Efficacy Data from Nexicart-2, the First U.S. Trial of a CAR-T (NXC-201) in Relapsed or Refractory (R/R) Light Chain (AL). ASCO Annual Meeting. Chicago, IL, June 3, 2025
ASH – 66th Annual American Society of Hematology Annual Meeting and Exposition (AL Amyloidosis) – Dec 9, 2024
E Lebel, N Asherie, M Assayag, S Elias, S Grisariu, B Avni, S Kfir-Erenfeld, T Dubnikov-Sharon, R Alexander-Shani, N Bessig, A Shehadeh, A Ishtay, S Pimienta, V Vaistein, E Zimran, M Pick, Y C. Cohen, I Avivi Mazza, C Cohen, P Stepensky, and M E Gatt. Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis. 66th ASH Annual Meeting and Exposition, San Diego, CA, December 9, 2024.
Phase 1 – AL Amyloidosis
Eyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, MD, Shlomo Elias, Miri Assayag, Tali Dubnikov-Sharon, Marjorie Pick, Rivka Alexander-Shani, Nomi Bessig, Shlomit Herr, Alaa Shehadeh, Aseel Ishtay, Shelly Pimienta, Vladimir Vainstein, Eran Zimran, Yael Cohen, Irit Avivi, Cyrille Cohen, Polina Stepensky, and Moshe E. Gatt. Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis. Journal of Clinical Oncology. December 9, 2024.